Related Experiment Videos
Treatment of essential hypertension with coenzyme Q10
P Langsjoen1, P Langsjoen, R Willis
1Institute for Biomedical Research, University of Texas at Austin 78712, USA.
Insights
Coenzyme Q10 (CoQ10) supplementation improved essential hypertension outcomes, reducing the need for antihypertensive drugs and enhancing cardiac function in patients. This study highlights CoQ10
Area of Science:
- Cardiology
- Nutritional Science
- Pharmacology
Background:
- Essential hypertension is a common cardiovascular condition requiring long-term management.
- Existing antihypertensive drug regimens may have limitations or side effects.
- Coenzyme Q10 (CoQ10) is an endogenous antioxidant with potential cardiovascular benefits.
Purpose of the Study:
- To evaluate the efficacy of CoQ10 as an add-on therapy for symptomatic essential hypertension.
- To assess the impact of CoQ10 on blood pressure, functional status, and antihypertensive drug requirements.
- To investigate changes in cardiac structure and function with CoQ10 supplementation.
Main Methods:
- A prospective observational study involving 109 patients with essential hypertension.
- CoQ10 (average 225 mg/day) was added to existing antihypertensive drug regimens.
- Patients were monitored for blood pressure, clinical status, and echocardiographic parameters.
Main Results:
- Significant improvement in New York Heart Association (NYHA) functional class (mean 2.40 to 1.36).
- 51% of patients reduced or discontinued antihypertensive medications.
- Improved left ventricular wall thickness and diastolic function observed in a subset of patients.
Conclusions:
- CoQ10 supplementation is effective in improving functional status and reducing antihypertensive drug burden in patients with essential hypertension.
- CoQ10 may positively impact cardiac structure and diastolic function.
- CoQ10 represents a promising adjunctive therapy for managing essential hypertension.
Abstract:
A total of 109 patients with symptomatic essential hypertension presenting to a private cardiology practice were observed after the addition of CoQ10 (average dose, 225 mg/day by mouth) to their existing antihypertensive drug regimen. In 80 per cent of patients, the diagnosis of essential hypertension was established for a year or more prior to starting CoQ10 (average 9.2 years). Only one patient was dropped from analysis due to noncompliance. The dosage of CoQ10 was not fixed and was adjusted according to clinical response and blood CoQ10 levels. Our aim was to attain blood levels greater than 2.0 micrograms/ml (average 3.02 micrograms/ml on CoQ10). Patients were followed closely with frequent clinic visits to record blood pressure and clinical status and make necessary adjustments in drug therapy. Echocardiograms were obtained at baseline in 88% of patients and both at baseline and during treatment in 39% of patients. A definite and gradual improvement in functional status was observed with the concomitant need to gradually decrease antihypertensive drug therapy within the first one to six months. Thereafter, clinical status and cardiovascular drug requirements stabilized with a significantly improved systolic and diastolic blood pressure. Overall New York Heart Association (NYHA) functional class improved from a mean of 2.40 to 1.36 (P < 0.001) and 51% of patients came completely off of between one and three antihypertensive drugs at an average of 4.4 months after starting CoQ10. Only 3% of patients required the addition of one antihypertensive drug. In the 9.4% of patients with echocardiograms both before and during treatment, we observed a highly significant improvement in left ventricular wall thickness and diastolic function.(ABSTRACT TRUNCATED AT 250 WORDS)